Sionna Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
SION$3.70+3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data) (Unaudited)
| March 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $82,695 | $37,788 |
| Marketable securities, current | 186,971 | 109,750 |
| Prepaid expenses and other current assets | 4,014 | 3,455 |
| Total current assets | 273,680 | 150,993 |
| Property and equipment, net | 2,393 | 2,466 |
| Marketable securities, noncurrent | 85,022 | 20,505 |
| Restricted cash | 962 | 962 |
| Operating lease right-of-use asset | 7,617 | 7,832 |
| Other assets | — | 2,994 |
| Total assets | $369,674 | $185,752 |
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $5,019 | $1,186 |
| Accrued expenses | 3,389 | 8,162 |
| Operating lease liability, current | 1,119 | 1,072 |
| Total current liabilities | 9,527 | 10,420 |
| Operating lease liability, noncurrent | 8,378 | 8,677 |
| Total liabilities | 17,905 | 19,097 |
| Commitments and contingencies (Note 7) | ||
| Series Seed convertible preferred stock, $0.001 par value, no shares and 3,963,963 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | 13,014 |
| Series A convertible preferred stock, $0.001 par value, no shares and 5,704,161 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | 25,235 |
| Series B convertible preferred stock, $0.001 par value, no shares and 11,370,621 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | 110,791 |
| Series C convertible preferred stock, $0.001 par value, no shares and 18,628,970 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | 181,328 |
| Total convertible preferred stock | — | 330,368 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of March 31, 2025 and December 31 2024, respectively; no shares issued or outstanding as of March 31, 2025 and December 31 2024 | — | — |
| Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of March 31, 2025 and December 31 2024, respectively; 44,124,394 and 4,798,721 shares issued, 44,092,117 and 4,722,763 shares outstanding as of March 31, 2025 and December 31, 2024, respectively | 44 | 5 |
| Additional paid-in capital | 548,992 | 17,000 |
| Accumulated other comprehensive income | 301 | 368 |
| Accumulated deficit | (197,568) | (181,086) |
| Total stockholders’ equity (deficit) | 351,769 | (163,713) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $369,674 | $185,752 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.